Literature DB >> 9837890

Effects of the inhibitors azide, dicyclohexylcarbodiimide, and aurovertin on nucleotide binding to the three F1-ATPase catalytic sites measured using specific tryptophan probes.

J Weber1, A E Senior.   

Abstract

Equilibrium nucleotide binding to the three catalytic sites of Escherichia coli F1-ATPase was measured in the presence of the inhibitors azide, dicyclohexylcarbodiimide, and aurovertin to elucidate mechanisms of inhibition. Fluorescence signals of beta-Trp-331 and beta-Trp-148 substituted in catalytic sites were used to determine nucleotide binding parameters. Azide brought about small decreases in Kd(MgATP) and Kd(MgADP). Notably, under MgATP hydrolysis conditions, it caused all enzyme molecules to assume a state with three catalytic site-bound MgATP and zero bound MgADP. These results rule out the idea that azide inhibits by "trapping" MgADP. Rather, azide blocks the step at which signal transmission between catalytic sites promotes multisite hydrolysis. Aurovertin bound with stoichiometry of 1.8 (mol/mol of F1) and allowed significant residual turnover. Cycling of the aurovertin-free beta-subunit catalytic site through three normal conformations was indicated by MgATP binding data. Aurovertin did not change the normal ratio of 1 bound MgATP/2 bound MgADP in catalytic sites. The results indicate that it acts to slow the switch of catalytic site affinities ("binding change step") subsequent to MgATP hydrolysis. Dicyclohexylcarbodiimide shifted the ratio of catalytic site-bound MgATP/MgADP from 1:2 to 1.6:1.4, without affecting Kd(MgATP) values. Like azide, it also appears to affect activity at the step after MgATP binding, in which signal transmission between catalytic sites promotes MgATP hydrolysis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9837890     DOI: 10.1074/jbc.273.50.33210

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

Review 1.  Inhibitory Mg-ADP-fluoroaluminate complexes bound to catalytic sites of F(1)-ATPases: are they ground-state or transition-state analogs?

Authors:  W S Allison; H Ren; C Dou
Journal:  J Bioenerg Biomembr       Date:  2000-10       Impact factor: 2.945

Review 2.  Medicinal chemistry of ATP synthase: a potential drug target of dietary polyphenols and amphibian antimicrobial peptides.

Authors:  Zulfiqar Ahmad; Thomas F Laughlin
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

Review 3.  ATP synthase and the actions of inhibitors utilized to study its roles in human health, disease, and other scientific areas.

Authors:  Sangjin Hong; Peter L Pedersen
Journal:  Microbiol Mol Biol Rev       Date:  2008-12       Impact factor: 11.056

Review 4.  ATP synthase: a molecular therapeutic drug target for antimicrobial and antitumor peptides.

Authors:  Zulfiqar Ahmad; Florence Okafor; Sofiya Azim; Thomas F Laughlin
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

5.  Does F1-ATPase have a catalytic site that preferentially binds MgADP?

Authors:  Hui Z Mao; Wesley D Gray; Joachim Weber
Journal:  FEBS Lett       Date:  2006-06-30       Impact factor: 4.124

6.  Phosphate exchange and ATP synthesis by DMSO-pretreated purified bovine mitochondrial ATP synthase.

Authors:  S Beharry; P D Bragg
Journal:  Biochem J       Date:  2001-01-15       Impact factor: 3.857

7.  A functionally inactive, cold-stabilized form of the Escherichia coli F1Fo ATP synthase.

Authors:  Mikhail A Galkin; Robert R Ishmukhametov; Steven B Vik
Journal:  Biochim Biophys Acta       Date:  2006-03-20

8.  Studies of nucleotide binding to the catalytic sites of Escherichia coli betaY331W-F1-ATPase using fluorescence quenching.

Authors:  Vladimir V Bulygin; Yakov M Milgrom
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-05       Impact factor: 11.205

9.  Sulfite inhibits the F1F0-ATP synthase and activates the F1F0-ATPase of Paracoccus denitrificans.

Authors:  Fermín Pacheco-Moisés; Fernando Minauro-Sanmiguel; Concepción Bravo; José J García
Journal:  J Bioenerg Biomembr       Date:  2002-08       Impact factor: 2.945

10.  Mechanistic basis for differential inhibition of the F1Fo-ATPase by aurovertin.

Authors:  Kathryn M Johnson; Lara Swenson; Anthony W Opipari; Rolf Reuter; Nawid Zarrabi; Carol A Fierke; Michael Börsch; Gary D Glick
Journal:  Biopolymers       Date:  2009-10       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.